Paper Details

  1. Home
  2. Paper Details

Treatment of chronic hepatitis C with recombinant interferon alfa-2b.

Author: ConteM C, MinerviniF, OrlandoR, PiazzaM, SantoroG, ScordinoF, TiseoD, TosoneG, VitaleD

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study compared two interferon alfa-2b treatment regimens for chronic hepatitis C. A higher dose (6 million units three times a week) for 12 months resulted in a higher percentage of patients with long-term improvement compared to a lower dose (3 million units for two months followed by 1.5 million units for 10 months). The higher dose group also had a higher rate of normalized liver enzymes that remained normal after treatment. Side effects were generally moderate and resolved on their own.
Paper Details　
Original Abstract of the Article :
In a study of 87 patients with chronic hepatitis C, 12 months' treatment with interferon alfa-2b at a dose of 6 million units (MU) three times per week seemed to be more effective than treatment with 3 MU three times a week for two months plus 1.5 MU three times a week for 10 months in increasing th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1136/gut.34.2_suppl.s128

データ提供：米国国立医学図書館（NLM）

Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa-2b

This study investigates the effectiveness of recombinant interferon alfa-2b in treating chronic hepatitis C. The research compares the efficacy of different dosage regimens and finds that higher doses are associated with greater long-term response rates, suggesting that adjusting the dosage can improve treatment outcomes.

Navigating the Desert of Hepatitis C Treatment with Interferon Alfa-2b

This study explores the effectiveness of different dosage regimens of interferon alfa-2b in treating chronic hepatitis C. Just as a camel adjusts its pace based on the terrain and availability of water, the researchers investigated the optimal dosage of this medication. The study found that higher doses were associated with greater long-term response rates, suggesting that adjusting the dosage can significantly improve treatment outcomes.

A New Oasis in the Desert of Hepatitis C

This research provides insights into the effectiveness of interferon alfa-2b in treating chronic hepatitis C. Just as a traveler searching for a life-giving oasis seeks the best path, researchers are continually seeking better treatments for this challenging disease. This study highlights the potential benefits of adjusting the dosage of interferon alfa-2b to improve treatment outcomes.

Dr. Camel's Conclusion

This study highlights the importance of careful dosage adjustments in treating chronic hepatitis C with interferon alfa-2b. The findings suggest that higher doses can lead to greater long-term response rates, offering a potential pathway to improving treatment outcomes. Just as a camel adjusts its pace and water intake to survive the desert, healthcare professionals can optimize treatment strategies by carefully considering the dosage of medications like interferon alfa-2b.

Date :
  1. Date Completed 1993-07-27
  2. Date Revised 2019-05-01
Further Info :

Pubmed ID

8314479

DOI: Digital Object Identifier

10.1136/gut.34.2_suppl.s128

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.